טוען...
MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myeloma
Multiple myeloma (MM) patients with the t(14;16) translocation have a poor prognosis, and unlike other molecular subgroups, their outcome has not improved with the introduction of bortezomib (Bzb). The mechanism underlying innate resistance of MM to Bzb is unknown. In the present study, we have inve...
שמור ב:
| הוצא לאור ב: | Blood |
|---|---|
| Main Authors: | , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
American Society of Hematology
2016
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5179331/ https://ncbi.nlm.nih.gov/pubmed/27793878 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2016-03-706077 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|